Kansas is currently home to 923 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
Recruiting
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host Disease (aGVHD). The first 5 participants enrolled in the study will receive a lower dose of MSCTC-0010. If none of the first 5 participants have treatment-related serious adverse events (TRSAEs) for 42 days, then the next 5 participants will receive a slightly higher dose... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/22/2024
Locations: Kansas University Cancer Center, Kansas City, Kansas
Conditions: Acute Graft Versus Host Disease
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
Recruiting
This phase II trial tests how well sacituzumab govitecan works in treating patients with cholangiocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced), that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a toxic agent, called SN-38. HRS7 is a form of targeted therapy because it attaches to s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Deep Functional Phenotyping of the ALA Lung Health Cohort
Recruiting
The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: the structure of the participants lungs' airways, the structure of blood vessels in the participants lungs and heart, and the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure... Read More
Gender:
All
Ages:
Between 25 years and 35 years
Trial Updated:
02/21/2024
Locations: University of Kansas, Kansas City, Kansas
Conditions: Lung Diseases
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Recruiting
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximatel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Recruiting
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Gender:
All
Ages:
Between 18 years and 110 years
Trial Updated:
02/21/2024
Locations: The University of Kansas Cancer Center (KUCC), Fairway, Kansas
Conditions: Lung Cancer, NSCLC, NSCLC Stage IV
Amyloidosis Incidence in High-Risk Cardiac Device Patients
Recruiting
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a n... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Midwest Heart & Vascular Specialists, Overland Park, Kansas
Conditions: Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type
ELUCIDATE FFRct Study
Recruiting
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Midwest Heart and Vascular Specialists, Overland Park, Kansas
Conditions: Coronary Artery Disease
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Recruiting
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Cardiovascular Research Institute of Kansas, Wichita, Kansas
Conditions: Acute Myocardial Infarction, Coronary Artery Disease
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas
Conditions: Refractory Chronic Cough
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
Recruiting
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. Cohort B, phase II 3rd lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Recruiting
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituxim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Cancer Center of Kansas, Wichita, Kansas
Conditions: Non Hodgkin Lymphoma
Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA
Recruiting
This study seeks to enhance long-term positive airway pressure (PAP) adherence among Spanish-speaking Hispanics, a group with known PAP outcomes disparities. This study will assess the feasibility of a linguistically and culturally adapted tele-management intervention (Automated Management, AM) for Spanish-speaking Hispanic adults with OSA.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Obstructive Sleep Apnea